Supplement evidence

065 / 575Fatty-acid form

EPA/DHA fish oil

View my plan →

The short answer

Raises EPA/DHA status; prescription products lower high triglycerides, while general prevention results are mixed.

Evidence and scope: Conditional or population-specific
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Benefit depends on the population, formulation, baseline status, and objective; results should not be generalized.
Before deciding: Key concern: Do not substitute supplement fish oil for prescription omega-3; review bleeding and atrial-fibrillation risk.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meeting usual needs250–500 mg/day EPA+DHA

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

High triglycerides4 g/day prescription product under clinical care

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with a fat-containing meal and split if reflux occurs.

Do not combine casually

Do not substitute supplement fish oil for prescription omega-3; review bleeding and atrial-fibrillation risk.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

4research papers in this ledger

49unique primary studies represented

28,016unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2021

Evidence contextPMID 34612056

Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials

Marine omega-3 supplementation was associated with more atrial fibrillation, with a larger relative estimate in trials above 1 g/day than at 1 g/day or less. The synthesis mixes EPA-only and EPA/DHA products and overlaps major trials already represented, so it is safety context rather than an independent efficacy count.

Published: 2021Duration: Long-term cardiovascular outcome trials

Study design and methods

Design: Systematic review and meta-analysis of 7 randomized cardiovascular outcome trials
Population: Adults enrolled in large cardiovascular outcome trials
Intervention: Long-term marine EPA and/or DHA supplementation versus control
Outcome: Incident atrial fibrillation and dose-response

Funding or conflict note: Excluded from aggregate totals because its seven trials overlap the generic omega-3 dossier and the ASCEND record above.

Open research record ↗

2018

Does not support the tested claimPMID 30146932 · NCT00135226

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus

Serious vascular events were 8.9% versus 9.2%, and the broader vascular composite was 11.4% versus 11.5%; neither differed significantly. This does not support routine combined EPA/DHA for primary cardiovascular prevention in diabetes.

Published: 2018Duration: Mean 7.4 yearsn=15,480 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled factorial trial
Population: 15,480 adults with diabetes but no known atherosclerotic cardiovascular disease
Intervention: Marine omega-3 840 mg/day (EPA 460 mg plus DHA 380 mg) or olive-oil placebo
Outcome: Serious vascular events, vascular events plus revascularization, mortality, and adverse events

Funding or conflict note: Mylan, formerly Solvay and Abbott, provided capsules and packaging funding and had nonvoting steering-committee representation but reportedly no data-analysis or publication-decision role.

Open research record ↗

2012

Does not support the tested claimPMID 22686415

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

The supplement modestly lowered triglycerides but did not reduce cardiovascular death, major vascular events, or all-cause death. A risk-factor change did not translate into clinical prevention at this dose and population.

Published: 2012Duration: Median 6.2 yearsn=12,536 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled factorial trial
Population: 12,536 adults with impaired glucose regulation or diabetes at high cardiovascular risk
Intervention: One 1-g capsule containing at least 900 mg omega-3 ethyl esters, including EPA and DHA, or placebo daily
Outcome: Cardiovascular death, major vascular events, all-cause death, and triglycerides

Open research record ↗

2009

Supports a specific usePMID 18774613

Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis

Fish oil lowered triglycerides by about 0.34 mmol/L, did not change total cholesterol, and produced very small HDL and LDL increases. This supports triglyceride lowering at multi-gram doses, not prevention of cardiovascular events.

Published: 2009Duration: Varied across 47 randomized trials47 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 47 placebo-controlled randomized trials
Population: Otherwise untreated adults with hyperlipidemia
Intervention: Fish oil averaging 3.25 g/day EPA and/or DHA versus placebo
Outcome: Triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol

Open research record ↗

Unscreened discovery appendix—not evidence415 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.